Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1949-1958

  Zhang, Lu ^a   Jia, Na ^b   Li, Jun ^a   Han, Yaping ^a   Cao, Wuchun ^b   Wang, Shixia ^a,c   Huang, Zuhu ^a   Lu, Shan ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Cross protection; H7N7; H7N9; Influenza infection; Neutralizing antibody; Vaccine

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H7N9; NEW ZEALAND WHITE (RABBIT); NONHUMAN; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H7N7); INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; RABBIT; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; RABBITS; VACCINES, DNA;

EID: 84903906895     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28795     Document Type: Article

References (40)

1. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587-93; PMID:14987882; http://dx.doi.org/10.1016/S0140-6736(04)15589-X
2. Palese P. Influenza: old and new threats. Nat Med 2004; 10(Suppl):S82-7; PMID:15577936; http://dx.doi.org/10.1038/nm1141
3. Webster RG, Govorkova EA. H5N1 influenza - continuing evolution and spread. N Engl J Med 2006; 355:2174-7; PMID:17124014; http://dx.doi.org/10.1056/NEJMp068205
4. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, et al.; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85; PMID:16192482; http://dx.doi.org/10.1056/NEJMra052211
5. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564-6; PMID:24224560; http://dx.doi.org/10.1056/NEJMc1313186
6. Couch RB, Patel SM, Wade-Bowers CL, Niño D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012; 7:e49704; PMID:23239968; http://dx.doi.org/10.1371/journal.pone.0049704
7. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER. C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.vaccine.2009.01.116
8. Webster RG. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis 1999; 28:225-9; PMID:10064231; http://dx.doi.org/10.1086/515123
9. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997; 15:865-8; PMID:9234535; http://dx.doi.org/10.1016/S0264-410X(96)00268-X
10. Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol 1995; 69:7712-7; PMID:7494280
11. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, et al.; VRC 304 and VRC 305 Study Teams. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7; PMID:22956656; http://dx.doi.org/10.1128/CVI.05663-11
12. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64; PMID:16714186; http://dx.doi.org/10.1016/S0140-6736(06)68656-X
13. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475-81; PMID:16150518; http://dx.doi.org/10.1016/j.vaccine.2005.08.012
14. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1:583-7; PMID:7585127; http://dx.doi.org/10.1038/nm0695-583
15. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al.; VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916-24; PMID:21975270; http://dx.doi.org/10.1016/S1473-3099(11)70240-7
16. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, Zhou A, Li J, Cao WC, Huang Z, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 2011; 6:e28757; PMID:22205966; http://dx.doi.org/10.1371/journal.pone.0028757
17. Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006; 80:11628-37; PMID:16987975; http://dx.doi.org/10.1128/JVI.01065-06
18. Tharakaraman K, Jayaraman A, Raman R, Viswanathan K, Stebbins NW, Johnson D, Shriver Z, Sasisekharan V, Sasisekharan R. Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. Cell 2013; 153:1486-93; PMID:23746830; http://dx.doi.org/10.1016/j.cell.2013.05.034
19. Lam TT, Wang J, Shen Y, Zhou B, Duan L, Cheung CL, Ma C, Lycett SJ, Leung CY, Chen X, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013; 502:241-4; PMID:23965623; http://dx.doi.org/10.1038/nature12515
20. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97; PMID:23577628; http://dx.doi.org/10.1056/NEJMoa1304459
21. WHO. Number of confirmed human cases of avian influenza A(H7N9) reported to World Health Organization. World Health Organization, 2013.
22. Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu Y, Li X, Yan J, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013; 381:1926-32; PMID:23643111; http://dx.doi.org/10.1016/S0140-6736(13)60938-1
23. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18:20453; PMID:23594575
24. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008; 26:3626-33; PMID:18538900; http://dx.doi.org/10.1016/j.vaccine.2008.04.073
25. Suguitan AL Jr., Cheng X, Wang W, Wang S, Jin H, Lu S. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 2011; 6:e21942; PMID:21760928; http://dx.doi.org/10.1371/journal.pone.0021942
26. Lu S. Two is better than one. Lancet Infect Dis 2011; 11:889-91; PMID:21975267; http://dx.doi.org/10.1016/S1473-3099(11)70256-0
27. Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine 2003; 21:1789-95; PMID:12686096; http://dx.doi.org/10.1016/S0264-410X(03)00074-4
28. Betts RF, Treanor JJ. Approaches to improved influenza vaccination. Vaccine 2000; 18:1690-5; PMID:10689150; http://dx.doi.org/10.1016/S0264-410X(99)00508-3
29. Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008; 26:3626-33; PMID:18538900; http://dx.doi.org/10.1016/j.vaccine.2008.04.073
30. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008; 26:2100-10; PMID:18378365; http://dx.doi.org/10.1016/j.vaccine.2008.02.033
31. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006; 24:4531-40; PMID:16140431; http://dx.doi.org/10.1016/j.vaccine.2005.08.023
32. Pappas C, Matsuoka Y, Swayne DE, Donis RO. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol 2007; 14:1425-32; PMID:17913860; http://dx.doi.org/10.1128/CVI.00174-07
33. Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus. PLoS One 2013; 8:e63856; PMID:23762234; http://dx.doi.org/10.1371/journal.pone.0063856
34. Min JY, Vogel L, Matsuoka Y, Lu B, Swayne D, Jin H, Kemble G, Subbarao K. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 2010; 84:11950-60; PMID:20810733; http://dx.doi.org/10.1128/JVI.01305-10
35. Xu Q, Chen Z, Cheng X, Xu L, Jin H. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS One 2013; 8:e76884; PMID:24130801; http://dx.doi.org/10.1371/journal.pone.0076884
36. Bos ME, Nielen M, Koch G, Stegeman A, De Jong MC. Effect of H7N1 vaccination on highly pathogenic avian influenza H7N7 virus transmission in turkeys. Vaccine 2008; 26:6322-8; PMID:18822335; http://dx.doi.org/10.1016/j.vaccine.2008.09.022
37. Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 2008; 26:1742-50; PMID:18336962; http://dx.doi.org/10.1016/j.vaccine.2008.01.036
38. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21:346-51; PMID:19500964; http://dx.doi.org/10.1016/j.coi.2009.05.016
39. Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, et al.; VRC 310 Study Team. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013; 208:418-22; PMID:23633407; http://dx.doi.org/10.1093/infdis/jit180
40. Almansour I, Chen H, Wang S, Lu S. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother 2013; 9:2049-59; PMID:23884239; http://dx.doi.org/10.4161/hv.25735